Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
- 21 May 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 69 (8), 1827-1832
- https://doi.org/10.2337/db20-0166
Abstract
We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes. Two oral insulin trials that did not show efficacy overall and had type 1 diabetes as the primary end point were analyzed: the Diabetes Prevention Trial–Type 1 (DPT-1) and the TrialNet oral insulin trials. Oral glucose tolerance tests at baseline and after 1 year of treatment were analyzed. Among those at high risk (with a Diabetes Prevention Trial–Type 1 Risk Score [DPTRS] ≥6.75), the area under the curve (AUC) C-peptide increased significantly from baseline to 1 year in each oral insulin group, whereas the AUC glucose increased significantly in each placebo group. At 1 year, the AUC C-peptide/AUC glucose (AUC Ratio) was significantly higher in the oral insulin group than in the placebo group in each trial (P < 0.05; P = 0.057 when adjusted for age in the TrialNet trial) and in both trials combined (P < 0.01 with or without adjustment for age). For a DPTRS <6.75, oral insulin groups did not differ from placebo groups in the AUC Ratio. The findings suggest that 1 year of treatment with oral insulin slows metabolic deterioration in individuals at high risk for type 1 diabetes. Moreover, the findings further suggest that metabolic end points can be useful adjuncts to the diagnostic end point in assessments of preventive treatments for the disorder.Keywords
This publication has 10 references indexed in Scilit:
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesThe New England Journal of Medicine, 2019
- β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosisJCI Insight, 2018
- Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 DiabetesJAMA, 2017
- Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 DiabetesJAMA, 2015
- Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 DiabetesDiabetes Care, 2014
- The use of intermediate endpoints in the design of type 1 diabetes prevention trialsDiabetologia, 2013
- Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History StudyDiabetes Care, 2011
- Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 ParticipantsDiabetes Care, 2009
- Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of OnsetDiabetes, 2009
- Effects of Oral Insulin in Relatives of Patients With Type 1 DiabetesDiabetes Care, 2005